A Conversation on Patient Equity, Screening Barriers, and Healthcare Innovation
54 million Americans remain unscreened for colorectal cancer¹—despite having access to proven screening options. Here's what's at stake: When CRC is caught early (Stage I), 5-year survival is 92%². When caught late (Stage IV), it's 14%². Every month the 54 million unscreened remain in the gap, approximately 3,800-4,200 develop CRC⁴—with 70% diagnosed at late stages³ where treatment options are limited and survival rates are poor.
There is a tool that reaches patients refusing traditional screening: blood-based ctDNA testing. It is clinically validated and FDA-approved. Yet as measurement systems evolve more slowly than clinical evidence matures, health systems, payers, and clinicians face real challenges in evaluating and implementing emerging screening approaches. How should organizations assess whether new screening technologies are ready for population-level accountability? What evidence is sufficient? And how do we balance rigorous evaluation with the urgent need to expand screening access to vulnerable populations?
This panel brings together health system, payer, and patient advocacy leaders to discuss how clinicians, health systems, and plans are evaluating emerging screening technologies. We'll explore what evidence matters most, how organizations are making informed decisions about which screening approaches to prioritize, and what's at stake—for patients and for public health—when screening access decisions are delayed.
Sponsored by:
